The Year in Review

Michael Charlton, MD

Semaglutide and Trizepatide

Rohit Loomba, MD

GLP-1/Glucagon Agonist Combinations: Pemvidutide and Servodutide

Phil Newsome, PhD, FRCPE, FMedSci

Pegozafermin, Efimosfermin and Newer FGF-21 Agonists

Mary Rinella, MD

Resmetirom and other THR-Beta Agonists

Mazen Noureddin, MD

Effruxifermin

Vlad Ratziu, MD, Phd

Panel Discussion

Break - Exhibit Hall / Poster Viewing

Recent Data in Elastography and Impact on Clinical Trials

Elf, Proc3 and Other Biomarkers: Better Than the Sum of Their Parts?

Novel Perspective in PDFF+CT1 and CAP and UDFF

Veeral Ajmera, MD

2 Orals

Regulatory Perspective on Biomarker Development

Panel Discussion

CME Symposium

Meetings and Self-Directed Learning

State of the Art: Hepatocyte Senescence as a Therapeutic Target

Anna Mae Diehl

Immune Exhaustion and Inflammatory Regulation of Disease Progression

Frank Tacke, MD, PhD, MBHA

Multi-Zonal Liver Organoids and MASH Modeling

Takanori Takebe

Endothelium as a Driver of Progression and Therapeutic Target

WNT-Beta Catenin in Regeneration and Fibrosis Regression

Satadarshan Paul Monga, MD

Q&A or Short Panel

Optimizing Oral Combination Therapy: Resmetirom and Other Agents

Meena Bansal

Genetic Targets: (e.g., Sirna Aso, Ciedb, GPR75, INHBE in Obesity and MASLD)

Naim Alkhouri, MD

GLP-GLU Analogs and Triple Agonists

Arun Sanyal, MD

GLP + GIP: To Agonize or Antagonize

Lanifibranor and Dapagliflozin, and Other Insulin Sensitizers

Manal Abdelmalek, MD, MPH, FAC, FACG, FAASLD

Top 5 Basic Science Papers in MASH

Vlad Ratzui MD, PhD

Stephen A. Harrison Award for Excellence in MASH

Cirrhosis Trials: Pearls for Optimal Trial Design

Mary Rinella, MD

Efficacy and Considerations for Reducing Malo: Lessons From Recent Trials

Phil Newsome, PhD, FRCPE, FMedSci

Clinical Trial Consideration METALD

Luis Antonio Diaz, MD

Debate: Is Resolution of Steatohepatitis a Necessary Regulatory Endpoint? Yes

Arun Sanyal, MD

Debate: Is Resolution of Steatohepatitis a Necessary Regulatory Endpoint? No

Naga Chalasani, MD

Panel Discussion

Case Based Patient Journey

Meena Bansal, MD

Reasonably Likely Surrogate Endpoint Update - And Implications on Trial Endpoints

Rohit Loomba, MD

Update in AI to Facilitate Clinical Trials

Naim Alkhouri, MD

Link Between Fibrosis Improvement and Outcomes - What is the Ground Truth?

Mazen Noureddin, MD

Is Fibrosis Regression the same as Cirrhosis Reversal : Yes/No

Arun Sanyal, MD

Panel Discussion

CME Symposium

Meetings, Poster Viewing, and Self-Directed Learning

Lecture: Interplay Between Adipose Tissue and GLP1, FGF21 in MASLD and METALD

Matthew Potoff, PhD

Lecture: Sterol Sensing and Cholesterol-Bile Acid Homeostatis in MASLD

Jay Horton, MD

Multiparametric Screening of MASH Clinical Candidates Using Human Liver Spheroids or N-Vitro Pre-Clinical Human Models for MASH

Francisco Verdeguer, PhD

2 or 3 Oral Presentations

Break - Exhibit Hall / Poster Viewing

Patient Expectation for Clinical Trials

Mike Betel

Lessons from the Accelerated Approval Program

Arun Sanyal, MD

Approach to Promising Combinations and Regulatory Path

Naim Alkhouri, MD

Reading the Regulatory Tealeaves: A NIT Only Trial?

Arun Sanyal, MD

What is an Ideal Regulatory Pathway for a Successful FDA Approval from a Pharma Viewpoint?

Kitty Yale & Michelle Long, MD, MSc

Panel Discussion

Wrap-Up

Rohit Loomba, MD